320 related articles for article (PubMed ID: 23623805)
1. Circulating tumor cells in breast cancer.
Banys M; Müller V; Melcher C; Aktas B; Kasimir-Bauer S; Hagenbeck C; Hartkopf A; Fehm T
Clin Chim Acta; 2013 Aug; 423():39-45. PubMed ID: 23623805
[TBL] [Abstract][Full Text] [Related]
2. Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization.
Riethdorf S; Pantel K
Pathobiology; 2008; 75(2):140-8. PubMed ID: 18544969
[TBL] [Abstract][Full Text] [Related]
3. Role of circulating tumor cells and disseminated tumor cells in primary breast cancer.
Hayashi N; Yamauchi H
Breast Cancer; 2012 Apr; 19(2):110-7. PubMed ID: 21643809
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of the detection of circulating tumor cells in breast cancer patients.
Banys M; Hartkopf AD; Krawczyk N; Becker S; Fehm T
Biomark Med; 2012 Feb; 6(1):109-18. PubMed ID: 22296204
[TBL] [Abstract][Full Text] [Related]
5. Tumor cell dissemination to the bone marrow and blood is associated with poor outcome in patients with metastatic breast cancer.
Hartkopf AD; Stefanescu D; Wallwiener M; Hahn M; Becker S; Solomayer EF; Fehm TN; Brucker SY; Taran FA
Breast Cancer Res Treat; 2014 Sep; 147(2):345-51. PubMed ID: 25151295
[TBL] [Abstract][Full Text] [Related]
6. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.
Giuliano M; Herrera S; Christiny P; Shaw C; Creighton CJ; Mitchell T; Bhat R; Zhang X; Mao S; Dobrolecki LE; Al-rawi A; Chen F; Veneziani BM; Zhang XH; Hilsenbeck SG; Contreras A; Gutierrez C; Jeselsohn RM; Rimawi MF; Osborne CK; Lewis MT; Schiff R; Trivedi MV
Breast Cancer Res; 2015 Jan; 17(1):3. PubMed ID: 25572662
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of circulating tumor cells in breast cancer patients.
Tao M; Ma D; Li Y; Zhou C; Li Y; Zhang Y; Duan W; Xu X; Wang R; Wu L; Liu H
Breast Cancer Res Treat; 2011 Aug; 129(1):247-54. PubMed ID: 21512769
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cells in breast cancer--current status and perspectives.
Banys-Paluchowski M; Krawczyk N; Meier-Stiegen F; Fehm T
Crit Rev Oncol Hematol; 2016 Jan; 97():22-9. PubMed ID: 26563820
[TBL] [Abstract][Full Text] [Related]
9. HER2-positive DTCs/CTCs in breast cancer.
Hartkopf AD; Banys M; Fehm T
Recent Results Cancer Res; 2012; 195():203-15. PubMed ID: 22527508
[TBL] [Abstract][Full Text] [Related]
10. Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics.
Onstenk W; Gratama JW; Foekens JA; Sleijfer S
Cancer Treat Rev; 2013 Nov; 39(7):691-700. PubMed ID: 23683721
[TBL] [Abstract][Full Text] [Related]
11. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis.
Janni W; Vogl FD; Wiedswang G; Synnestvedt M; Fehm T; Jückstock J; Borgen E; Rack B; Braun S; Sommer H; Solomayer E; Pantel K; Nesland J; Friese K; Naume B
Clin Cancer Res; 2011 May; 17(9):2967-76. PubMed ID: 21415211
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of circulating tumor cells in primary and metastatic breast cancer.
Aurilio G; Sciandivasci A; Munzone E; Sandri MT; Zorzino L; Cassatella MC; Verri E; Rocca MC; Nolè F
Expert Rev Anticancer Ther; 2012 Feb; 12(2):203-14. PubMed ID: 22316368
[TBL] [Abstract][Full Text] [Related]
13. Circulating levels of transforming growth factor-βeta (TGF-β) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer.
Divella R; Daniele A; Savino E; Palma F; Bellizzi A; Giotta F; Simone G; Lioce M; Quaranta M; Paradiso A; Mazzocca A
Anticancer Res; 2013 Apr; 33(4):1491-7. PubMed ID: 23564790
[TBL] [Abstract][Full Text] [Related]
14. Circulating and disseminated tumor cells in the management of breast cancer.
Ross JS; Slodkowska EA
Am J Clin Pathol; 2009 Aug; 132(2):237-45. PubMed ID: 19605818
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
16. Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.
Deng G; Krishnakumar S; Powell AA; Zhang H; Mindrinos MN; Telli ML; Davis RW; Jeffrey SS
BMC Cancer; 2014 Jun; 14():456. PubMed ID: 24947048
[TBL] [Abstract][Full Text] [Related]
17. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.
Krishnamurthy S; Cristofanilli M; Singh B; Reuben J; Gao H; Cohen EN; Andreopoulou E; Hall CS; Lodhi A; Jackson S; Lucci A
Cancer; 2010 Jul; 116(14):3330-7. PubMed ID: 20564098
[TBL] [Abstract][Full Text] [Related]
18. Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application?
Lang JE; Hall CS; Singh B; Lucci A
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1463-72. PubMed ID: 17944570
[TBL] [Abstract][Full Text] [Related]
19. Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies.
Müller V; Alix-Panabières C; Pantel K
Eur J Cancer; 2010 May; 46(7):1189-97. PubMed ID: 20347588
[TBL] [Abstract][Full Text] [Related]
20. Micrometastatic disease in breast cancer: clinical implications.
Ignatiadis M; Georgoulias V; Mavroudis D
Eur J Cancer; 2008 Dec; 44(18):2726-36. PubMed ID: 19056036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
